Does the media prefer CELU or ACXP?

In the previous week, Celularity and Celularity both had 3 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 0.97 beat Celularity's score of 0.38 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acurx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACXP or SNTI more profitable?

Acurx Pharmaceuticals' return on equity of -153.92% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Senti Biosciences N/A -532.05% -103.35%

Does the media favor ACXP or SNTI?

In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Acurx Pharmaceuticals and 2 mentions for Senti Biosciences. Acurx Pharmaceuticals' average media sentiment score of 0.97 beat Senti Biosciences' score of 0.93 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acurx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACXP or TAOX more profitable?

Acurx Pharmaceuticals' return on equity of -153.92% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Synaptogenix N/A -163.40% -133.47%

Does the media favor ACXP or TAOX?

In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for Acurx Pharmaceuticals and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.28 beat Acurx Pharmaceuticals' score of 0.97 indicating that Synaptogenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acurx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synaptogenix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TVRD or ACXP more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -64.17% -43.90% Acurx Pharmaceuticals N/A -153.92% -101.69%

Does the media refer more to CRVO or ACXP?

In the previous week, CervoMed had 2 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 5 mentions for CervoMed and 3 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.97 beat CervoMed's score of 0.60 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Acurx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Acurx Pharmaceuticals (ACXP) Competitors

$1.60 -0.01 (-0.62%)

Closing price 06/10/2026 04:00 PM Eastern

Extended Trading

$1.58 -0.02 (-1.19%)

As of 06/10/2026 06:51 PM Eastern

Compare

ACXP vs. CELU, SNTI, TAOX, TVRD, and CRVO

Should you buy Acurx Pharmaceuticals stock or one of its competitors? MarketBeat compares Acurx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acurx Pharmaceuticals include Celularity (CELU), Senti Biosciences (SNTI), Synaptogenix (TAOX), Tvardi Therapeutics (TVRD), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.

How does Acurx Pharmaceuticals compare to Celularity?

Celularity (NASDAQ:CELU) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Celularity. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.84	-$91.72M	-$3.33	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Celularity has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, indicating that its share price is 309% less volatile than the broader market.

Celularity presently has a consensus target price of $6.00, indicating a potential upside of 675.59%. Acurx Pharmaceuticals has a consensus target price of $31.00, indicating a potential upside of 1,837.50%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Celularity and Celularity both had 3 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 0.97 beat Celularity's score of 0.38 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acurx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.0% of Celularity shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Acurx Pharmaceuticals has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Summary

Celularity beats Acurx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Senti Biosciences?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Acurx Pharmaceuticals and 2 mentions for Senti Biosciences. Acurx Pharmaceuticals' average media sentiment score of 0.97 beat Senti Biosciences' score of 0.93 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acurx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Senti Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Acurx Pharmaceuticals currently has a consensus target price of $31.00, indicating a potential upside of 1,837.50%. Senti Biosciences has a consensus target price of $10.00, indicating a potential upside of 941.56%. Given Acurx Pharmaceuticals' higher probable upside, equities research analysts plainly believe Acurx Pharmaceuticals is more favorable than Senti Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Acurx Pharmaceuticals' return on equity of -153.92% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Senti Biosciences	N/A	-532.05%	-103.35%

Acurx Pharmaceuticals has a beta of -2.09, indicating that its share price is 309% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

Acurx Pharmaceuticals has higher earnings, but lower revenue than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Senti Biosciences	$20K	1,495.36	-$61.44M	-$1.92	N/A

Summary

Acurx Pharmaceuticals beats Senti Biosciences on 8 of the 15 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Synaptogenix?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Acurx Pharmaceuticals' return on equity of -153.92% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Synaptogenix	N/A	-163.40%	-133.47%

Acurx Pharmaceuticals has a beta of -2.09, suggesting that its stock price is 309% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Acurx Pharmaceuticals currently has a consensus target price of $31.00, suggesting a potential upside of 1,837.50%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Acurx Pharmaceuticals is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Acurx Pharmaceuticals has higher earnings, but lower revenue than Synaptogenix. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Synaptogenix	$300K	90.89	-$28.74M	-$13.28	N/A

In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for Acurx Pharmaceuticals and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.28 beat Acurx Pharmaceuticals' score of 0.97 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acurx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Synaptogenix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Acurx Pharmaceuticals beats Synaptogenix on 10 of the 14 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Tvardi Therapeutics presently has a consensus target price of $46.17, suggesting a potential upside of 1,609.88%. Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 1,837.50%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Tvardi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Acurx Pharmaceuticals has lower revenue, but higher earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	3.55	-$18.21M	-$3.10	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

In the previous week, Tvardi Therapeutics had 5 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 8 mentions for Tvardi Therapeutics and 3 mentions for Acurx Pharmaceuticals. Tvardi Therapeutics' average media sentiment score of 1.40 beat Acurx Pharmaceuticals' score of 0.97 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tvardi Therapeutics	Positive
Acurx Pharmaceuticals	Positive

Tvardi Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, indicating that its stock price is 309% less volatile than the broader market.

Tvardi Therapeutics' return on equity of -64.17% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tvardi Therapeutics beats Acurx Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to CervoMed?

CervoMed (NASDAQ:CRVO) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Acurx Pharmaceuticals has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	5.20	-$26.97M	-$3.28	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

CervoMed has a beta of -0.68, meaning that its stock price is 168% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, meaning that its stock price is 309% less volatile than the broader market.

Acurx Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

CervoMed currently has a consensus price target of $22.60, indicating a potential upside of 904.44%. Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 1,837.50%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, CervoMed had 2 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 5 mentions for CervoMed and 3 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.97 beat CervoMed's score of 0.60 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Acurx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

25.2% of CervoMed shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 35.4% of CervoMed shares are held by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

CervoMed beats Acurx Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Acurx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACXP vs. The Competition

Export

Metric	Acurx Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.92M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.32%	2.67%	5.61%
P/E Ratio	-0.40	18.83	24.41	23.63
Price / Sales	N/A	292.16	500.91	102.25
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	0.77	8.00	10.43	6.70
Net Income	-$7.97M	$23.89M	$3.56B	$337.26M
7 Day Performance	-9.60%	-5.43%	-2.94%	-2.43%
1 Month Performance	-26.61%	-4.18%	-0.39%	0.19%
1 Year Performance	-77.14%	36.70%	20.10%	23.15%

Acurx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACXP Acurx Pharmaceuticals	3.8799 of 5 stars	$1.60 -0.6%	$31.00 +1,837.5%	-77.4%	$6.92M	N/A	N/A	3	Short Interest Decrease
CELU Celularity	2.4744 of 5 stars	$1.06 -0.9%	$6.00 +466.0%	-60.6%	$30.68M	$26.55M	N/A	220	Gap Up
SNTI Senti Biosciences	3.5514 of 5 stars	$0.98 +0.4%	$8.75 +789.4%	-68.2%	$30.65M	$20K	N/A	4	News Coverage
TAOX Synaptogenix	0.7738 of 5 stars	$4.02 -4.5%	N/A	N/A	$30.03M	$300K	N/A	4	News Coverage Positive News Gap Down
TVRD Tvardi Therapeutics	3.0407 of 5 stars	$3.17 -1.6%	$53.60 +1,590.9%	-89.6%	$29.74M	N/A	N/A	80	Positive News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACXP) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. CELU, SNTI, TAOX, TVRD, and CRVO

How does Acurx Pharmaceuticals compare to Celularity?

Summary

How does Acurx Pharmaceuticals compare to Senti Biosciences?

Summary

How does Acurx Pharmaceuticals compare to Synaptogenix?

Summary

How does Acurx Pharmaceuticals compare to Tvardi Therapeutics?

Summary

How does Acurx Pharmaceuticals compare to CervoMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. CELU, SNTI, TAOX, TVRD, and CRVO

How does Acurx Pharmaceuticals compare to Celularity?

Which has higher valuation & earnings, CELU or ACXP?

Which has more risk and volatility, CELU or ACXP?

Do analysts recommend CELU or ACXP?

Does the media prefer CELU or ACXP?

Do insiders and institutionals believe in CELU or ACXP?

Is CELU or ACXP more profitable?

Summary

How does Acurx Pharmaceuticals compare to Senti Biosciences?

Does the media favor ACXP or SNTI?

Do insiders & institutionals believe in ACXP or SNTI?

Do analysts rate ACXP or SNTI?

Is ACXP or SNTI more profitable?

Which has more risk and volatility, ACXP or SNTI?

Which has stronger earnings & valuation, ACXP or SNTI?

Summary

How does Acurx Pharmaceuticals compare to Synaptogenix?

Is ACXP or TAOX more profitable?

Which has more risk and volatility, ACXP or TAOX?

Do insiders and institutionals have more ownership in ACXP or TAOX?

Do analysts prefer ACXP or TAOX?

Which has better valuation & earnings, ACXP or TAOX?

Does the media favor ACXP or TAOX?

Summary

How does Acurx Pharmaceuticals compare to Tvardi Therapeutics?

Do analysts prefer TVRD or ACXP?

Which has better valuation and earnings, TVRD or ACXP?

Does the media prefer TVRD or ACXP?

Which has more volatility & risk, TVRD or ACXP?

Is TVRD or ACXP more profitable?

Do insiders and institutionals have more ownership in TVRD or ACXP?

Summary

How does Acurx Pharmaceuticals compare to CervoMed?

Which has higher earnings & valuation, CRVO or ACXP?

Which has more risk & volatility, CRVO or ACXP?

Is CRVO or ACXP more profitable?

Do analysts prefer CRVO or ACXP?

Does the media refer more to CRVO or ACXP?

Do institutionals and insiders believe in CRVO or ACXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools